23:03 , Jun 29, 2017 |  BC Innovations  |  Translation in Brief

New Therapeutic Targets and Biomarkers: June 2017

New Therapeutic Targets and Biomarkers: June 2017 Select top therapeutic targets and biomarkers covered by BioCentury or added to the BCIQ database during June 2017. Therapeutic targets are defined as any protein, gene or other molecule...
21:00 , Jun 22, 2017 |  BC Innovations  |  Targets & Mechanisms

Exosomes deliver

Codiak BioSciences Inc. founder Raghu Kalluri has published the first animal data demonstrating exosomes can be used as drug delivery vehicles to treat cancer -- not just diagnose it. The findings also mark the unveiling...
20:34 , May 23, 2017 |  BC Innovations  |  Distillery Therapeutics

Cancer

INDICATION: Melanoma Cell culture studies suggest inhibiting PRKCD, PKCE or RASGRP3 could help treat GNAQ-mutant uveal melanoma. Levels of RASGRP3 were higher in five human GNAQ-mutant uveal melanoma cell lines than in four human cutaneous melanoma...
19:08 , Mar 17, 2017 |  BioCentury  |  Finance

Personal stakes

To generate interest from LPs in their inaugural healthcare fund, the duo behind Biomatics Capital Partners personally invested in eight companies that would eventually form the core of the fund’s portfolio ahead of a $70...
19:05 , Mar 17, 2017 |  BioCentury  |  Finance

CRISPR pigs

Drawn by CRISPR’s potential to address the organ transplant shortage with safer xenotransplants, Biomatics Capital Partners and Arch Venture Partners co-led a $38 million series A round for eGenesis Inc. intended to fund the company...
04:16 , Mar 16, 2017 |  BC Extra  |  Financial News

eGenesis raises $38M series A

Xenotransplantation play eGenesis Inc. (Boston, Mass.) raised the first tranche of a $38 million series A round co-led by Biomatics Capital Partners and Arch Venture Partners. Khosla Ventures, Alta Partners, Alexandria Real Estate Equities, Heritage...
14:41 , Mar 15, 2017 |  BC Extra  |  Financial News

Biomatics closes debut fund at $200M

Biomatics Capital Partners closed its debut fund at $200 million, exceeding its $150 million target. The firm was founded last year by managing directors Boris Nikolic, former chief advisor for science and technology to Bill...
07:00 , Aug 4, 2016 |  BC Innovations  |  Distillery Therapeutics

Therapeutics: Tumor necrosis factor receptor superfamily member 21 (TNFRSF21; DR6); receptor-interacting serine-threonine kinase 1 (RIPK1; RIP1); RIPK3 (RIP3)

Cancer INDICATION: Cancer; breast cancer; lung cancer; melanoma Cell culture and mouse studies suggest inhibiting the necroptosis-related proteins RIPK1, RIPK3 or TNFRSF21 could help treat metastatic breast, lung, melanoma and other metastatic cancers. In co-cultures of human...
07:00 , Jun 16, 2016 |  BC Innovations  |  Distillery Therapeutics

Therapeutics: Deoxyribonuclease I like 3 (DNASE1L3)

Autoimmune disease INDICATION: Lupus Patient sample and mouse studies suggest DNASE1L3 could help treat lupus caused by mutations in the gene. In vitro, sera from DNASE1L3-deficient mice and lupus patients digested less DNA from apoptotic cells and...
07:00 , Apr 25, 2016 |  BioCentury  |  Analyst Picks & Changes

Analyst picks & changes

Analyst picks & changes Analyst picks & changesCompanyBankAnalystCoverageOpinionWk chg4/22 clsChiasma Inc. (NASDAQ:CHMA)CowenRitu BaralDowngradeMarket perform (from outperform)-62%$3.83 William BlairTim LugoDowngradeMarket perform (from outperform)Baral also removed her $32 target after FDA issued a complete response letter to an...